Guildford, UK, 9 January 2012: ReNeuron announces that it is presenting at the Biotech Showcase 2012 conference taking place in San Francisco on 9-11 January.
Michael Hunt, Chief Executive Officer of ReNeuron, will participate in a panel session focusing on stroke at the Regenerative Medicine Insight Track at the conference, on 10 January.
The Regenerative Medicine Insight Track event was developed by the Alliance for Regenerative Medicine (ARM), a Washington, DC-based international organisation representing the interests of the regenerative medicine community. ReNeuron is a founding member of the Alliance for Advanced Therapies, the European branch of ARM. The Regenerative Medicine Insight Track meeting will start with the Second Annual State of the Industry Briefing, followed by a series of analyst-led panels focused on therapeutic areas where regenerative medicine holds great promise.
Further details about the conference can be found at www.ebdgroup.com/bts/index.
Further details about ARM can be found at www.alliancerm.org.
Michael Hunt, Chief Executive Officer – ReNeuron +44 (0) 1483 302560
Lisa Baderoon, Mark Court, Isabel Podda +44 (0) 20 7466 5000
David Hart +44 (0) 20 7776 6550
Daniel Stewart & Company plc
ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron’s lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research. The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.
ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as “should”, “expects”, “estimates”, “believes” or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron’s actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.